Up-regulated expression and activation of the. orphan chemokine receptor, CCRL2, in rheumatoid arthritis

被引:54
作者
Galligan, CL
Matsuyama, W
Matsukawa, A
Mizuta, H
Hodge, DR
Howard, OMZ
Yoshimura, T
机构
[1] NCI, Frederick, MD 21702 USA
[2] Kumamoto Univ, Grad Sch Med Sci, Kumamoto, Japan
来源
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 06期
关键词
D O I
10.1002/art.20275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by a cellular influx and destruction of the joint architecture. Chemokines characteristically regulate leukocyte recruitment and activation. Chemokine (CC motif) receptor-like 2 (CCRL2) is an orphan receptor with homology to other CC chemokine receptors. We undertook this study to examine CCRL2 expression in RA, cytokine regulation of expression, and the source of a putative ligand in an attempt to determine the role of this receptor during inflammation. Methods. Expression of CCRL2 on joint-infiltrating leukocytes was examined by immunocytochemistry. In vitro studies evaluated CCRL2 expression in primary neutrophils using Northern and Western blotting and reverse transcriptase-polymerase chain reaction. HEK 293 cells expressing two splice variants of CCRL2 (HEK/CCRL2A or HEK/CCRL2B) were generated with a retroviral expression system, and their migration in response to fractions of synovial fluid (SF) from RA patients was examined using a 48-well chamber. Results. CCRL2 expression was observed on all infiltrating neutrophils and on some macrophages obtained from the SF of 5 RA patients. In vitro studies of primary neutrophils revealed that CCRL2 messenger RNA (mRNA) was rapidly up-regulated following stimulation with lipopolysaccharide (1 mug/ml) or tumor necrosis factor (5 ng/ml). The mRNA for both CCRL2A and CCRL2B were expressed in cytokine-stimulated neutrophils. Cells expressing either of these splice variants migrated in response to a fraction of RA SF. Conclusion. CCRL2 expression is up-regulated on synovial neutrophils of RA patients. Inflammatory products present in the SF activate this receptor, indicating that CCRL2 is a functional receptor that may be involved in the pathogenesis of RA.
引用
收藏
页码:1806 / 1814
页数:9
相关论文
共 32 条
[1]  
AHUJA SK, 1994, J BIOL CHEM, V269, P26381
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases [J].
Brühl, H ;
Wagner, K ;
Kellner, H ;
Schattenkirchner, M ;
Schlöndorff, D ;
Mack, M .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 126 (03) :551-559
[4]   MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION OF 2 MONOCYTE CHEMOATTRACTANT PROTEIN-1 RECEPTORS REVEALS ALTERNATIVE SPLICING OF THE CARBOXYL-TERMINAL TAILS [J].
CHARO, IF ;
MYERS, SJ ;
HERMAN, A ;
FRANCI, C ;
CONNOLLY, AJ ;
COUGHLIN, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (07) :2752-2756
[5]   Cloning and characterization of a novel human chemokine receptor [J].
Fan, P ;
Kyaw, H ;
Su, K ;
Zeng, ZZ ;
Augustus, M ;
Carter, KC ;
Li, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (01) :264-268
[6]   Role of cytokines in rheumatoid arthritis [J].
Feldmann, M ;
Brennan, FM ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :397-440
[7]   Evolving concepts of rheumatoid arthritis [J].
Firestein, GS .
NATURE, 2003, 423 (6937) :356-361
[8]  
GALLIGAN C, 2003, CHEM IMMUNOLOGY ALLE, P24
[9]   An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model [J].
Gong, JH ;
Ratkay, LG ;
Waterfield, JD ;
ClarkLewis, I .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :131-137
[10]  
Gupta SK, 1999, J IMMUNOL, V163, P2368